 |
市场调查报告书
商品编码
1550704
全球Bortezomib市场：按产品类型、按应用、按最终用户、按地区Bortezomib Market, By Product Type, By Application, By End User, By Geography |
||||||
预计2024年全球Bortezomib市场规模为2,454万美元，预计2031年将达3,315万美元，2024年至2031年复合年增长率为4.4%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 2454万美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 4.40% | 2031年价值预测 | 3315万美元 |
Bortezomib（通常称为 Velcade）是一种蛋白酶体抑制剂，可作为标靶癌症治疗药物。Bortezomib已被证明是治疗多发性骨髓瘤和其他癌症的有效选择。全球癌症盛行率不断上升，加上老年人口越来越容易罹患骨髓瘤，可能会推动Bortezomib的需求。由于Bortezomib被指定为孤儿药，製造商正在积极投资该市场。然而，药物专利到期可能会阻碍市场成长。Bortezomib令人鼓舞的治疗功效和不断扩大的应用可能会在不久的将来为全球Bortezomib市场的成长提供利润丰厚的机会。
市场动态：
全球Bortezomib市场的成长是由全球癌症负担日益增加所推动的。市场成长的原因是多发性骨髓瘤盛行率不断上升、对该疾病的核准增加以及更容易患骨髓瘤的老年人口不断增加。据美国国家癌症美国称，2020 年美国报告了超过 15 万例多发性骨髓瘤病例。此外，与Bortezomib相关的高治疗成本和研发成本可能会阻碍市场成长。创新药的专利将于2015年至2020年间到期，这将鼓励学名药的生产，并可能对原厂药Velcade的销售产生负面影响。然而，正在进行的评估Bortezomib在其他疾病中的潜力的试验可能会带来新的机会。
本研究的主要特点
本报告对全球Bortezomib市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球Bortezomib市场的主要企业进行了分析。
本研究涵盖的主要企业包括强生公司、工业、Fresenius SE &Co.KGaA、Dr. Reddy's Laboratories Ltd 和 Scion Pharma LLC。
从这份报告中获得的见解将帮助负责人和公司经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球Bortezomib市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球Bortezomib市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章 市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 併购场景
第四章全球Bortezomib市场：依产品类型（2019-2031）
- 注射
- 注射用粉剂
第五章全球Bortezomib市场：依应用分类（2019-2031）
- 多发性骨髓瘤
- 套细胞淋巴瘤
- 其他骨髓恶性肿瘤
第六章全球Bortezomib市场：依最终用户分类（2019-2031）
- 医院
- 肿瘤门诊
- 门诊手术中心
- 其他（研究机构、癌症中心）
第七章全球Bortezomib市场：按地区（2019-2031）
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
第八章 竞争格局
- Hikma Pharmaceuticals
- Pfizer
- Meitheal Pharmaceuticals
- Novartis International AG
- Bristol Myers Squibb
- NATCO Pharma
- Teva Pharmaceuticals
- Reddy's Laboratories
- Gland Pharma
- Shilpa Medicare
- Qilu Pharmaceutical
- Scion Pharmaceuticals
- Farmhispania Group
- Coresyn
- Chem-Stone（Guangzhou）
- Hubei Honch Pharmaceutical
- Vinkem Labs
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals
第九章 分析师建议
- Wheel of Fortune
- 分析师观点
- Coherent Opportunity Map（COM）
第10章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global bortezomib market is estimated to be valued at USD 24.54 Mn in 2024 and is expected to reach USD 33.15 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 24.54 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.40% | 2031 Value Projection: | US$ 33.15 Mn |
Bortezomib, commonly known as Velcade, is a proteasome inhibitor that acts as a targeted cancer therapy. It has proven to be an effective treatment option for multiple myeloma and other cancers. Increasing prevalence of cancer worldwide along with growing geriatric population susceptible to myeloma can boost demand for Bortezomib. Drug being designated with orphan drug status has encouraged manufacturers to invest in this market. However, patent expiry of the drug can hamper the market growth. Promising therapeutic efficacy and expanding applications of Bortezomib can offer lucrative opportunities for the global bortezomib market growth in the near future.
Market Dynamics:
Global bortezomib market growth is driven by rising cancer burden globally. The market growth can be attributed to increasing incidence rates of multiple myeloma, approval for additional indications, and expanding geriatric population base who are more prone to developing myeloma. As per the National Cancer Institute, more than 150,000 cases of multiple myeloma were reported in the US in 2020. High treatment and R&D costs associated with Bortezomib can hamper the market growth. Patent expiry of innovative drug between 2015 to 2020 has encouraged production of generic versions, and this can negatively impact the sales of branded Velcade. However, ongoing trials evaluating the potential of Bortezomib in other disease indications can present new opportunities.
Key features of the study:
This report provides in-depth analysis of the global bortezomib market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bortezomib market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Takeda Pharmaceutical Company Ltd, Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Ltd, and Scion Pharma LLC
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global bortezomib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bortezomib market
Detailed Segmentation-
- By Product Type Insights (Revenue, USD Mn, 2019 - 2031)
- Injection
- Powder for Injection
- By Application Insights (Revenue, USD Mn, 2019 - 2031)
- Multiple Myeloma
- Mantle Cell Lymphoma
- Other Hematological Malignancies
- By End User Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals
- Oncology Clinics
- Ambulatory Surgical Centers
- Others (Research Institutes, Cancer Centers)
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hikma Pharmaceuticals
- Pfizer
- Meitheal Pharmaceuticals
- Novartis International AG
- Bristol Myers Squibb
- NATCO Pharma
- Teva Pharmaceuticals
- Reddy's Laboratories
- Gland Pharma
- Shilpa Medicare
- Qilu Pharmaceutical
- Scion Pharmaceuticals
- Farmhispania Group
- Coresyn
- Chem-Stone (Guangzhou)
- Hubei Honch Pharmaceutical
- Vinkem Labs
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Bortezomib Market, By Product Type
- Global Bortezomib Market, By Application
- Global Bortezomib Market, By End User
- Global Bortezomib Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Bortezomib Market, By Product Type, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Powder for Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Global Bortezomib Market, By Application, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Mantle Cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Other Hematological Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Bortezomib Market, By End User, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Oncology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others (Research Institutes, Cancer Centers)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Bortezomib Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 220 - 2031, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Meitheal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NATCO Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gland Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shilpa Medicare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Qilu Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Scion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Farmhispania Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Coresyn
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chem-Stone (Guangzhou)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hubei Honch Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vinkem Labs
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
Capecitabine市场：按配方、分销管道、最终用户、药物类型划分 - 2025-2030 年全球预测
PARP 抑制剂市场：按药物类型、按应用、按分销管道、按地区
Capecitabine市场：按适应症、药物类型和最终用户分类：2024-2033 年全球机会分析和产业预测
Epirubicin市场：按产品、剂量、应用、分销管道 - 全球预测 2024-2030
紫杉醇注射液市场，按适应症类型、按应用、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测
全球紫杉醇注射液市场，依癌症类型、配销通路、地理位置。
全球 PARP 抑制剂市场评估：按药物类型、应用、最终用户、分销管道、地区、机会和预测（2017-2031）
蛋白酶体抑制剂（PI）市场：现况分析与预测（2023-2030）
PARP 抑制剂药物治疗市场：按药物、适应症、配销通路- 全球预测 2024-2030
2030 年Capecitabine市场预测：按类型、适应症、分销管道、最终用户和地区进行的全球分析